NCT06873724进行中（未招募）1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
- 试验地点
- 2
- 主要终点
- Treatment emergent adverse events
研究概览
简要总结
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy men and women
- •Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
排除标准
- •Participation in more than one cohort
- •Evidence of clinically significant abnormality or disease
- •Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
- •History of severe allergic reactions or hypersensitivity
- •Donation or loss of >1 unit of whole blood within 1 month prior to dosing
研究组 & 干预措施
SAD Cohorts 1-6 Experimental Arm
Experimental
Participants will receive a single dose of SPY003-207 in a dose escalation format
干预措施: SPY003-207 (Drug)
SAD Cohorts 1-6 Placebo Arm
Placebo Comparator
Participants will receive a single dose of placebo
干预措施: Placebo (Other)
结局指标
主要结局
Treatment emergent adverse events
时间窗: Up to 63 weeks
Incidence, severity, and causal relationship of TEAEs
次要结局
- Cmax(Up to 63 weeks)
- Tmax(Up to 63 weeks)
- t1/2(Up to 63 weeks)
- AUC(Up to 63 weeks)
- ADA(Up to 63 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of SPY002-072 in Healthy VolunteersHealthyNCT06622070Spyre Therapeutics, Inc.40
已完成
1 期
A Study of SPY002-091 in Healthy VolunteersHealthyNCT06672718Spyre Therapeutics, Inc.50
已完成
1 期
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy SubjectsHealthy SubjectsNCT03980080OSE Immunotherapeutics63
已完成
1 期
Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy ParticipantsSafety IssuesHealthy VolunteersNCT05112159Nanjing Immunophage Biotech Co., Ltd76
已完成
1 期
Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189DepressionNCT01310881Neuralstem Inc.35